Charles W. Newton Acquires 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton purchased 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $0.56 per share, with a total value of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $0.58 on Thursday. The company has a market cap of $171.76 million, a price-to-earnings ratio of -0.74 and a beta of -0.41. The firm has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.89. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Lyell Immunopharma by 312.7% in the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock valued at $332,000 after acquiring an additional 182,315 shares during the period. SG Americas Securities LLC increased its position in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after acquiring an additional 59,182 shares during the period. Jane Street Group LLC increased its position in Lyell Immunopharma by 63.7% in the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock valued at $397,000 after acquiring an additional 111,917 shares during the period. State Street Corp increased its position in Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after acquiring an additional 71,233 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Lyell Immunopharma in the 3rd quarter valued at approximately $52,000. Institutional investors own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.